Indication
ERBB2 Gene Duplication
1 clinical trial
2 products
1 drug
Clinical trial
Disitamab Vedotin（RC48）Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Product
Disitamab VedotinDrug
pyrotinib